FIELD: pharmaceutics.
SUBSTANCE: present invention relates to a method of producing a pharmaceutical composition containing deferasirox. Method includes steps of producing dispersion of deferasirox with at least one excipient in water, homogenisation of deferasirox and at least one excipient to obtain a homogeneous dispersion of deferasirox and grinding said homogeneous dispersion until suspension with average particle size less than or equal to 2,000 nm is obtained. Also described is a pharmaceutical composition of deferasirox nanoparticles obtained using said method. Composition is intended for oral administration and is in form of a tablet. Disclosed composition is used in preparing a drug for treating chronic iron overload.
EFFECT: method provides a stable and effective deferasirox composition with improved solubility.
25 cl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POWDER CONTAINING DEFERASIROX AND METHOD OF PREPARATION THEREOF | 2016 |
|
RU2695616C1 |
| PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN | 2008 |
|
RU2484816C2 |
| ABIRATERONE ACETATE FORMULATION | 2014 |
|
RU2732136C2 |
| PHARMACEUTICAL ANTIRETROVIRAL COMPOSITION | 2013 |
|
RU2648457C2 |
| COMPOSITIONS AND METHODS OF ACTIVE PHARMACEUTICAL INGREDIENT STABILISATION | 2005 |
|
RU2391115C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| PERORAL MEDICINAL FORM WITH IMMEDIATE RELEASE OF POORLY-SOLUBLE ACTIVE SUBSTANCE | 2005 |
|
RU2382649C2 |
